| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 28 | 2023 | 313 | 3.470 |
Why?
|
| Orthopedics | 9 | 2020 | 137 | 2.150 |
Why?
|
| Femoral Neoplasms | 5 | 2020 | 19 | 1.500 |
Why?
|
| Internship and Residency | 8 | 2020 | 1081 | 1.430 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 140 | 1.400 |
Why?
|
| Sarcoma | 14 | 2020 | 216 | 1.370 |
Why?
|
| Clinical Competence | 8 | 2020 | 806 | 1.180 |
Why?
|
| Osteosarcoma | 8 | 2020 | 159 | 0.940 |
Why?
|
| Femur | 5 | 2020 | 107 | 0.910 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2019 | 123 | 0.860 |
Why?
|
| Limb Salvage | 4 | 2020 | 38 | 0.830 |
Why?
|
| Bone Lengthening | 2 | 2020 | 4 | 0.730 |
Why?
|
| Bone Nails | 2 | 2017 | 15 | 0.720 |
Why?
|
| Artificial Limbs | 1 | 2020 | 20 | 0.680 |
Why?
|
| Personnel Staffing and Scheduling | 3 | 2012 | 98 | 0.660 |
Why?
|
| Work Schedule Tolerance | 2 | 2012 | 37 | 0.650 |
Why?
|
| Specialization | 1 | 2020 | 69 | 0.640 |
Why?
|
| Bone Transplantation | 6 | 2022 | 67 | 0.630 |
Why?
|
| Osteotomy | 3 | 2018 | 37 | 0.620 |
Why?
|
| Career Choice | 1 | 2020 | 153 | 0.590 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 14 | 0.570 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 120 | 0.550 |
Why?
|
| Curriculum | 3 | 2019 | 581 | 0.520 |
Why?
|
| Patient Safety | 3 | 2020 | 221 | 0.500 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2015 | 10 | 0.500 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 39 | 0.490 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 56 | 0.480 |
Why?
|
| Education, Medical, Graduate | 4 | 2020 | 411 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 82 | 0.470 |
Why?
|
| Bacteremia | 1 | 2015 | 105 | 0.460 |
Why?
|
| Decision Making | 1 | 2020 | 680 | 0.440 |
Why?
|
| Curettage | 2 | 2024 | 14 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2017 | 3509 | 0.430 |
Why?
|
| Workload | 2 | 2012 | 130 | 0.430 |
Why?
|
| Bone Cysts, Aneurysmal | 2 | 2011 | 7 | 0.420 |
Why?
|
| Neoplasm Staging | 14 | 2013 | 2035 | 0.420 |
Why?
|
| Bone Cysts | 2 | 2024 | 8 | 0.410 |
Why?
|
| Humans | 71 | 2024 | 92337 | 0.400 |
Why?
|
| Teaching | 1 | 2013 | 146 | 0.390 |
Why?
|
| Argon Plasma Coagulation | 1 | 2011 | 6 | 0.380 |
Why?
|
| Medical Errors | 1 | 2012 | 115 | 0.370 |
Why?
|
| Osteochondroma | 2 | 2010 | 8 | 0.350 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 51 | 0.340 |
Why?
|
| Tibia | 2 | 2010 | 78 | 0.340 |
Why?
|
| Catheter Ablation | 3 | 2011 | 254 | 0.340 |
Why?
|
| Male | 40 | 2023 | 43925 | 0.330 |
Why?
|
| Extremities | 6 | 2014 | 177 | 0.330 |
Why?
|
| Child | 17 | 2024 | 7334 | 0.320 |
Why?
|
| Hip Joint | 1 | 2010 | 54 | 0.320 |
Why?
|
| Female | 40 | 2021 | 47893 | 0.310 |
Why?
|
| Joint Instability | 1 | 2010 | 91 | 0.300 |
Why?
|
| Competency-Based Education | 2 | 2019 | 38 | 0.290 |
Why?
|
| Orthopedic Surgeons | 2 | 2019 | 16 | 0.290 |
Why?
|
| Biopsy | 7 | 2011 | 1194 | 0.280 |
Why?
|
| Adult | 33 | 2021 | 27532 | 0.280 |
Why?
|
| Radiography | 8 | 2024 | 795 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 657 | 0.280 |
Why?
|
| Retrospective Studies | 18 | 2024 | 9703 | 0.260 |
Why?
|
| Adolescent | 15 | 2021 | 9504 | 0.260 |
Why?
|
| Osteoma, Osteoid | 2 | 2005 | 8 | 0.250 |
Why?
|
| Endometriosis | 1 | 2005 | 59 | 0.240 |
Why?
|
| Muscular Diseases | 1 | 2005 | 66 | 0.240 |
Why?
|
| Treatment Outcome | 12 | 2024 | 8740 | 0.230 |
Why?
|
| Tarsal Bones | 2 | 2021 | 11 | 0.220 |
Why?
|
| United States | 10 | 2020 | 7348 | 0.220 |
Why?
|
| Diagnosis, Differential | 7 | 2023 | 1592 | 0.220 |
Why?
|
| Pelvic Bones | 2 | 2000 | 44 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2680 | 0.210 |
Why?
|
| Fracture Fixation, Internal | 1 | 2004 | 83 | 0.200 |
Why?
|
| Shoulder Joint | 2 | 2004 | 96 | 0.200 |
Why?
|
| Bone Substitutes | 1 | 2021 | 10 | 0.190 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 9 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2021 | 14 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3775 | 0.190 |
Why?
|
| Middle Aged | 26 | 2020 | 27030 | 0.180 |
Why?
|
| Rhabdomyosarcoma | 2 | 1998 | 42 | 0.170 |
Why?
|
| Leg Length Inequality | 1 | 2020 | 2 | 0.170 |
Why?
|
| Time Factors | 7 | 2020 | 5430 | 0.170 |
Why?
|
| Fractures, Bone | 2 | 2017 | 146 | 0.170 |
Why?
|
| Child, Preschool | 6 | 2021 | 3818 | 0.170 |
Why?
|
| Veins | 1 | 2020 | 96 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.170 |
Why?
|
| Occupational Health | 1 | 2020 | 36 | 0.170 |
Why?
|
| Humerus | 1 | 1999 | 31 | 0.160 |
Why?
|
| Arteries | 1 | 2020 | 179 | 0.160 |
Why?
|
| Thymoma | 1 | 2019 | 31 | 0.160 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 149 | 0.160 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2019 | 6 | 0.160 |
Why?
|
| Choristoma | 1 | 2019 | 63 | 0.160 |
Why?
|
| Cognitive Aging | 1 | 2019 | 8 | 0.160 |
Why?
|
| Learning Curve | 1 | 2019 | 23 | 0.150 |
Why?
|
| Models, Educational | 1 | 2019 | 49 | 0.150 |
Why?
|
| Cartilage, Articular | 1 | 1999 | 72 | 0.150 |
Why?
|
| Fibrous Dysplasia, Monostotic | 1 | 2018 | 1 | 0.150 |
Why?
|
| Disabled Persons | 1 | 1999 | 72 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 145 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2019 | 901 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 259 | 0.140 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 1 | 2017 | 2 | 0.140 |
Why?
|
| Metatarsal Bones | 1 | 2017 | 8 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1398 | 0.140 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.140 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2017 | 7 | 0.140 |
Why?
|
| Leg Bones | 2 | 2011 | 7 | 0.140 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2017 | 13 | 0.140 |
Why?
|
| Neoplasm Metastasis | 6 | 2006 | 1071 | 0.130 |
Why?
|
| Cadaver | 1 | 2017 | 191 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2019 | 800 | 0.130 |
Why?
|
| Cysts | 2 | 2010 | 103 | 0.130 |
Why?
|
| Internet | 1 | 2019 | 331 | 0.130 |
Why?
|
| Sex Factors | 1 | 2020 | 1095 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 17 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 530 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 166 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2020 | 364 | 0.130 |
Why?
|
| Joint Diseases | 2 | 2010 | 48 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2017 | 126 | 0.130 |
Why?
|
| Prosthesis Design | 1 | 2017 | 303 | 0.120 |
Why?
|
| Joint Prosthesis | 1 | 2015 | 26 | 0.120 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2458 | 0.120 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 99 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 328 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 313 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2729 | 0.120 |
Why?
|
| Aged | 18 | 2020 | 19943 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 6624 | 0.110 |
Why?
|
| Surgeons | 1 | 2019 | 265 | 0.110 |
Why?
|
| Survival Rate | 8 | 2009 | 1927 | 0.110 |
Why?
|
| Patient Selection | 3 | 2010 | 689 | 0.110 |
Why?
|
| Surgery Department, Hospital | 1 | 2014 | 44 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 812 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2013 | 304 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 1015 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 226 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2014 | 96 | 0.100 |
Why?
|
| Radius | 2 | 2022 | 31 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 108 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2020 | 2369 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 619 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2014 | 552 | 0.100 |
Why?
|
| Sarcoma, Ewing | 2 | 2010 | 43 | 0.100 |
Why?
|
| Accreditation | 1 | 2012 | 62 | 0.100 |
Why?
|
| Arm Bones | 1 | 2011 | 2 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 164 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 866 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2014 | 339 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 305 | 0.090 |
Why?
|
| Knee Joint | 2 | 2002 | 162 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 1733 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 400 | 0.090 |
Why?
|
| Osseointegration | 1 | 2010 | 10 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 1180 | 0.080 |
Why?
|
| Prognosis | 9 | 2006 | 3872 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2009 | 2556 | 0.080 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 498 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2011 | 210 | 0.080 |
Why?
|
| Allografts | 2 | 2022 | 197 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 1181 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 1763 | 0.080 |
Why?
|
| Eosinophilic Granuloma | 1 | 2008 | 11 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2014 | 2978 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1079 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1919 | 0.070 |
Why?
|
| Wound Healing | 1 | 2010 | 373 | 0.070 |
Why?
|
| Ileum | 1 | 2008 | 168 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 130 | 0.070 |
Why?
|
| Argon | 1 | 2007 | 10 | 0.070 |
Why?
|
| Laser Coagulation | 1 | 2007 | 56 | 0.070 |
Why?
|
| Clinical Protocols | 3 | 2010 | 156 | 0.060 |
Why?
|
| Risk Factors | 5 | 2020 | 5704 | 0.060 |
Why?
|
| Age Factors | 3 | 2013 | 1905 | 0.060 |
Why?
|
| Intergenerational Relations | 1 | 2005 | 5 | 0.060 |
Why?
|
| Prosthesis Implantation | 2 | 2005 | 130 | 0.060 |
Why?
|
| Thigh | 1 | 2005 | 40 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2005 | 53 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 569 | 0.060 |
Why?
|
| Chicago | 2 | 2020 | 1466 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 144 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 400 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2024 | 16 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2004 | 16 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 996 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1150 | 0.050 |
Why?
|
| Proportional Hazards Models | 4 | 2003 | 871 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2008 | 406 | 0.050 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 14 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 403 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2003 | 24 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2003 | 132 | 0.050 |
Why?
|
| Chromans | 1 | 2002 | 29 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 390 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2014 | 694 | 0.050 |
Why?
|
| Incidence | 2 | 1999 | 1661 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 284 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 75 | 0.050 |
Why?
|
| Lymphoma | 1 | 2003 | 267 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1807 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2023 | 280 | 0.050 |
Why?
|
| Sclerosis | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 227 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 131 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 128 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6916 | 0.040 |
Why?
|
| Range of Motion, Articular | 2 | 1999 | 169 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 42 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 612 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2020 | 24 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2020 | 127 | 0.040 |
Why?
|
| Cytogenetic Analysis | 2 | 2010 | 71 | 0.040 |
Why?
|
| Bones of Upper Extremity | 1 | 1999 | 1 | 0.040 |
Why?
|
| Arthroplasty | 1 | 2020 | 34 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2013 | 485 | 0.040 |
Why?
|
| Safety Management | 1 | 2020 | 56 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 443 | 0.040 |
Why?
|
| Pathology, Clinical | 2 | 2010 | 36 | 0.040 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1999 | 16 | 0.040 |
Why?
|
| Spinal Nerve Roots | 1 | 1999 | 19 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2014 | 955 | 0.040 |
Why?
|
| World Health Organization | 2 | 2010 | 114 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1999 | 18 | 0.040 |
Why?
|
| Bone Plates | 1 | 1999 | 29 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1999 | 44 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 1999 | 38 | 0.040 |
Why?
|
| Reoperation | 2 | 1999 | 654 | 0.040 |
Why?
|
| Sarcoma, Synovial | 2 | 2013 | 21 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 107 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 42 | 0.040 |
Why?
|
| Epirubicin | 2 | 2009 | 14 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 43 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2009 | 48 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 78 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 53 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 1999 | 127 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2019 | 201 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 694 | 0.040 |
Why?
|
| Femur Head | 1 | 2017 | 8 | 0.040 |
Why?
|
| Recovery of Function | 1 | 1999 | 317 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2448 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 102 | 0.030 |
Why?
|
| Professionalism | 1 | 2017 | 25 | 0.030 |
Why?
|
| Foot Diseases | 1 | 2017 | 12 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 270 | 0.030 |
Why?
|
| Disease Progression | 1 | 2001 | 1503 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 229 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 205 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2005 | 1511 | 0.030 |
Why?
|
| Sports Medicine | 1 | 2017 | 58 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2010 | 601 | 0.030 |
Why?
|
| Spinal Diseases | 1 | 2017 | 77 | 0.030 |
Why?
|
| Hand | 1 | 2017 | 145 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2006 | 2394 | 0.030 |
Why?
|
| Athletic Injuries | 1 | 2017 | 99 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1743 | 0.030 |
Why?
|
| Algorithms | 1 | 2004 | 1956 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2017 | 197 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 219 | 0.030 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2013 | 5 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 3110 | 0.030 |
Why?
|
| Liposarcoma | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2005 | 431 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 2013 | 87 | 0.030 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1993 | 10 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 2013 | 46 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 463 | 0.030 |
Why?
|
| Prospective Studies | 2 | 1999 | 4468 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 172 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 595 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1052 | 0.020 |
Why?
|
| Cell Movement | 2 | 2005 | 797 | 0.020 |
Why?
|
| Foot Deformities | 1 | 1991 | 9 | 0.020 |
Why?
|
| Mutation | 1 | 2002 | 4204 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2368 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 798 | 0.020 |
Why?
|
| Mice | 1 | 2005 | 12110 | 0.020 |
Why?
|
| Gait | 1 | 1991 | 83 | 0.020 |
Why?
|
| France | 1 | 2010 | 51 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 701 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1991 | 178 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 209 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 2009 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 296 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 475 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 314 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 868 | 0.020 |
Why?
|
| Infant | 1 | 1994 | 3218 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2009 | 235 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 602 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2005 | 12 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 456 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2005 | 35 | 0.020 |
Why?
|
| Data Collection | 1 | 2005 | 379 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 398 | 0.010 |
Why?
|
| Hemangioendothelioma | 1 | 2003 | 9 | 0.010 |
Why?
|
| Ameloblastoma | 1 | 2003 | 9 | 0.010 |
Why?
|
| Neurofibrosarcoma | 1 | 2003 | 5 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 46 | 0.010 |
Why?
|
| Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Chordoma | 1 | 2003 | 30 | 0.010 |
Why?
|
| Sample Size | 1 | 2003 | 126 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 206 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 828 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 299 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2002 | 39 | 0.010 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2002 | 3 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2002 | 50 | 0.010 |
Why?
|
| Chondroblastoma | 1 | 2002 | 5 | 0.010 |
Why?
|
| Synovial Cyst | 1 | 2002 | 11 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 48 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 2002 | 20 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 88 | 0.010 |
Why?
|
| Bursitis | 1 | 2002 | 14 | 0.010 |
Why?
|
| Fibula | 1 | 2002 | 31 | 0.010 |
Why?
|
| Lipoma | 1 | 2002 | 26 | 0.010 |
Why?
|
| Fibroma | 1 | 2002 | 33 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2002 | 53 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 269 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 123 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 312 | 0.010 |
Why?
|
| Hematoma | 1 | 2002 | 107 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 531 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 453 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 266 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 767 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 470 | 0.010 |
Why?
|
| Polymethyl Methacrylate | 1 | 1999 | 15 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1477 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1999 | 18 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 217 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 2498 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2669 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1720 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 1999 | 197 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1939 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1310 | 0.010 |
Why?
|
| Cause of Death | 1 | 1997 | 270 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 188 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1592 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1576 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1684 | 0.010 |
Why?
|
| Prevalence | 1 | 1997 | 1294 | 0.010 |
Why?
|
| Electromyography | 1 | 1991 | 191 | 0.010 |
Why?
|
| Pain | 1 | 1991 | 406 | 0.000 |
Why?
|
| Animals | 1 | 2005 | 28003 | 0.000 |
Why?
|